<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biosciences Biotechnology Research Asia</journalTitle>
          <issn>0973-1245</issn>
            <publicationDate>2024-07-01</publicationDate>
    
        <volume>21</volume>
        <issue>2</issue>

 
    <startPage>467</startPage>
    <endPage>474</endPage>

	 
      <doi>10.13005/bbra/3239 </doi>
        <publisherRecordId>51165</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Ferroptosis: Implications in Diseases and Potential Treatment Approaches</title>

    <authors>
	 


      <author>
       <name>Komal Kontam R</name>

 
		
	<affiliationId>1</affiliationId>
      </author>
    

	 


      <author>
       <name>Nivetha M</name>


		
	<affiliationId>1</affiliationId>

      </author>
    

	 


      <author>
       <name>N Venkateswaramurthy</name>

		
	<affiliationId>2</affiliationId>
      </author>
    

	


	


	
    </authors>
    
	    <affiliationsList>
	    
		
		<affiliationName affiliationId="1">Department of Pharmacy Practice,  JKKN College of Pharmacy, Kumarapalayam, TamilNadu, India.</affiliationName>
    

		
		
		
		
		
	  </affiliationsList>






    <abstract language="eng">Ferroptosis is a recently recognized iron dependent form of regulated cell death. Ferroptotic cells are smaller than normal mitochondria and are usually cristae in structure. Ras-selective lethal small molecule (RSLs) induced cell death is blocked by anti-oxidants and iron chelators. Thus, the term ferroptosis often refers to a non-apoptotic, iron dependent form of regulated cell death (RCD). In 2016, it was found that there are 4 classes of inducers of ferroptosis which includes erastin, glutamate, sorafenib, RSL-3, FIN 56, etc and other reagents like CCL4 and artesunate may induce ferroptosis in liver and pancreatic cancer cells. Age-related and degenerative diseases necessarily cause an increase in brain iron levels, which can be seen in both post-mortem and living samples. Hepatochromatosis and other tissues and illnesses with ferroptosis have both been researched. The presence of ferroptosis is consistent with a variety of clinicopathologic dementia characteristics. Other neurodegenerative illnesses have comparable symptoms. A variety of pharmacological treatment for inhibiting ferroptosis in diseases have been reported like iron chelators, lipophilic antioxidant and β-mercaptoethanol.</abstract>

    <fullTextUrl format="html">https://www.biotech-asia.org/vol21no2/ferroptosis-implications-in-diseases-and-potential-treatment-approaches/</fullTextUrl>



      <keywords language="eng">
        <keyword>Apoptosis; Degenerative disease; Erastin;  Ferroptosis; Iron chelators; Regulated cell death</keyword>
      </keywords>

  </record>
</records>